Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

Last updated: December 8, 2023
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting

Phase

4

Condition

Hemangioma

Treatment

Propranolol three times a day

Propranolol twice a day

Timolol

Clinical Study ID

NCT05479123
HSC-MS-22-0246
  • Ages < 18
  • All Genders

Study Summary

The purpose of this study is to assess the baseline sleep pattern disruption for patients starting oral propranolol at the standard BID dosing regimen compared to the control (timolol) group and to determine if there is a significant improvement in the sleep patterns in infants taking oral propranolol on the TID dosing regimen versus the control (timolol) group

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • clinically diagnosed hemangiomas.
  • English or Spanish speaking only

Exclusion

Exclusion Criteria:

  • Parents who do not consent to the study.
  • Significant cardiac or pulmonary disease who are unable to tolerate oral propranolol

Study Design

Total Participants: 174
Treatment Group(s): 3
Primary Treatment: Propranolol three times a day
Phase: 4
Study Start date:
June 23, 2022
Estimated Completion Date:
July 31, 2025

Connect with a study center

  • The University of Texas Health Science Center at Houston

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.